Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, China; Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China.
Biochem Pharmacol. 2022 Dec;206:115306. doi: 10.1016/j.bcp.2022.115306. Epub 2022 Oct 28.
Mounting evidence indicates that adverse intrauterine conditions increase offspring's hypercholesterolemia susceptibility in adulthood. This study aimed to confirm prenatal dexamethasone exposure (PDE)-induced hypercholesterolemia susceptibility in female adult offspring rats, and elucidate its intrauterine programming mechanism. Pregnant Wistar rats were injected with dexamethasone subcutaneously (0, 0.1 and 0.2 mg/kg·d) from gestational day (GD) 9 to 20. Serum and liver of the female offspring were collected at GD21 and postnatal week (PW) 12 and 28. PDE offspring showed elevated serum total cholesterol (TCH) levels and a cholesterol phenotype of high cardiovascular disease risk at PW12 and PW28. The histone acetylation levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) and its expression were consistently increased in the PDE offspring both in utero and after birth. Moreover, PDE promoted glucocorticoid receptor (GR) nuclear translocation and miR-133a-3p expression and inhibited sirtuin-1 (Sirt1) expression in the fetal liver. In vitro, dexamethasone increased intracellular and supernatant TCH levels and miR-133a-3p expression, decreased SIRT1 expression, and promoted HMGCR histone acetylation and expression in bone marrow mesenchymal stem cells (BMSCs) hepatoid differentiated cells and HepG2 cell line. GR siRNA, miR-133a-3p inhibitor or SIRT1 overexpression reversed dexamethasone-induced downstream molecular and phenotypic changes. Furthermore, elevated TCH levels in umbilical cord blood and increased HMGCR expression in peripheral blood mononuclear cells (PBMCs) were observed in human female neonates who had received dexamethasone treatment during pregnancy. In conclusion, PDE can cause persistent enhancement of hepatic cholesterol synthesis function before and after birth through GR/miR-133a-3p/Sirt1 pathway, eventually leading to increased hypercholesterolemia susceptibility in female offspring rats.
越来越多的证据表明,宫内不良环境会增加后代成年后患高胆固醇血症的易感性。本研究旨在证实产前地塞米松暴露(PDE)诱导雌性成年后代大鼠的高胆固醇血症易感性,并阐明其宫内编程机制。妊娠 Wistar 大鼠从妊娠第 9 天至 20 天每天皮下注射地塞米松(0、0.1 和 0.2mg/kg·d)。在妊娠第 21 天和产后第 12 周和 28 周收集雌性后代的血清和肝脏。PDE 后代在产后第 12 周和 28 周时表现出血清总胆固醇(TCH)水平升高和高心血管疾病风险的胆固醇表型。在 PDE 后代中,HMGCR 的组蛋白乙酰化水平及其表达在宫内和出生后均持续升高。此外,PDE 促进糖皮质激素受体(GR)核易位和 miR-133a-3p 的表达,并抑制胎儿肝脏中的 Sirtuin-1(Sirt1)表达。在体外,地塞米松增加骨髓间充质干细胞(BMSCs)肝样分化细胞和 HepG2 细胞系的细胞内和上清液 TCH 水平及 miR-133a-3p 的表达,降低 SIRT1 表达,并促进 HMGCR 组蛋白乙酰化和表达。GR siRNA、miR-133a-3p 抑制剂或 SIRT1 过表达逆转了地塞米松诱导的下游分子和表型变化。此外,在接受孕期地塞米松治疗的人类女性新生儿中,脐带血 TCH 水平升高,外周血单核细胞(PBMCs)中 HMGCR 表达增加。综上所述,PDE 可通过 GR/miR-133a-3p/Sirt1 通路在出生前后持续增强肝脏胆固醇合成功能,最终导致雌性后代大鼠高胆固醇血症易感性增加。